The investment bank also initiated coverage of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters with a Hold rating.
There were more winners than losers in the 2015 GWDN Index, but some lost big.
Their approach detects resistance to carbapenems, drugs commonly used in hospitals and in patients with infections already resistant to other antibiotics.
The program will run for two years, and Bruker said that it will repurchase its common stock from time to time in amounts and at prices that it deems appropriate.
The approach combines collection of ions via IMS with rapid quadrupole switching to enable the fragmentation of multiple simultaneously elution precursor ions.
Discounting the negative effects of divestitures and currency exchange rates, the company posted Q3 organic growth of 8 percent and beat analysts’ consensus estimates.
Overall, analyst Bryan Brokmeier said he is bullish on the space in spite of uncertainty in the general global markets.
The company posted organic revenue growth of 1 percent and beat analysts' estimate on the top and bottom lines.
The conference was relatively light on new mass spec launches, with many vendors focusing instead on more targeted applications of existing technology.
The buyback program will target the repurchase of less than 1 percent of shares and is not set for a specific number of shares or dollar amount.
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.